Mosaic and AgBiome Announce Collaboration to Develop Biological Alternatives to Enhance Soil Health theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Mar 04, 2021
Elanco Animal Health Incorporated has launched a new product that it says brings the cattle industry powerful new options for fast, smooth and flexible protection against bovine respiratory disease (BRD) one of the deadliest diseases affecting U.S. cattle.
New NUPLURA PH+ builds on the proven performance of NUPLURA PH against Mannheimia haemolytica, while adding protection against common viral causes of BRD, including BVD Types 1 and 2 and IBR.
NUPLURA PH+ provides protective immunity against M. haemolytica in as little as 10 days, which is the fastest immunity claim on the market. M. haemolytica is the primary bacterial cause of pneumonia in cattle. NUPLURA PH+ protects against M. haemolytica and other causes of BRD in calves, as well as in animals at risk for BRD during weaning, branding, shipping, commingling and other times of elevated stress.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Elanco Achieves Important Innovation Milestones, Momentum to Start 2021
February 19, 2021 GMT
GREENFIELD, Ind. (BUSINESS WIRE) Feb 19, 2021
Elanco Animal Health Incorporated (NYSE: ELAN) today announces four important innovation milestones, including two product approvals, amid a string of recent progress on its innovation commitments.
Farm Animal
Yesterday, the U.S. FDA approved Increxxa™ (tulathromycin injection) for the treatment of bovine respiratory disease (BRD) and swine respiratory disease (SRD).
Earlier this week, Health Canada approved Experior™ 50, (lubabegron), a new concentration of Experior for the reduction of ammonia gas emissions per kilogram of live weight and hot carcass weight during the last 14 to 91 days on feed, representing the first animal health product with proven environmental benefit.
Feb 01, 2021
Elanco Animal Health Incorporated recently announced the next step in its ongoing efforts to improve operational efficiency. The proposed actions are focused on streamlining processes and delivering increased efficiency in functional areas while, importantly, improving the productivity of Elanco’s investments in innovation. These actions build on the September 2020 restructuring that focused mainly on optimizing the combined Elanco and Bayer Animal Health commercial operations.
The initiatives announced, which were approved by the Elanco board of directors on Jan. 25, include the consolidation of R&D activities to align capabilities to the newly combined innovation portfolio and support the company’s Innovation, Portfolio and Productivity (IPP) strategy. Elanco intends to close R&D sites in Manukau, New Zealand and Cuxhaven, Germany, subject to appropriate local consultation processes. Elanco will also reduce duplication and optimize structures in U.S. operations,